Savient Pharmaceuticals Earnings: Everything You Must Know Now
Savient Pharmaceuticals, Inc. (NASDAQ:SVNT) had a loss and missed Wall Street’s expectations, AND came up short on beating the revenue expectation. The revenue miss is a negative sign to shareholders seeking high growth out of the company.
Savient Pharmaceuticals, Inc. Earnings Cheat Sheet
Results: Adjusted Earnings Per Share increased to $-0.34 in the quarter versus EPS of $-0.49 in the year-earlier quarter.
Revenue: Rose 32.86% to $4.69 million from the year-earlier quarter.
Actual vs. Wall St. Expectations: Savient Pharmaceuticals, Inc. reported adjusted EPS loss of $0.34 per share. By that measure, the company missed the mean analyst estimate of $-0.31. It missed the average revenue estimate of $5.65 million.
Quoting Management: There was no comment from management.
Key Stats (on next page)…
Revenue decreased 5.25% from $4.95 million in the previous quarter. EPS increased to $-0.34 in the quarter versus EPS of $-0.39 in the previous quarter.
Looking Forward: Analysts have a more negative outlook for the company’s next-quarter performance. Over the past three months, the average estimate for next quarter’s earnings has fallen from a loss of $0.25 to a loss $0.28. For the current year, the average estimate has moved down from a loss of $1.12 to a loss of $1.14 over the last ninety days.
Stocks with improving earnings metrics are worthy of your extra attention. In fact, “E = Earnings Are Increasing Quarter-Over-Quarter” is a core component of our CHEAT SHEET investing framework for this very reason. Don’t waste another minute – click here and get our CHEAT SHEET stock picks now.
(Company fundamentals provided by Xignite Financials. Email any earnings discrepancies to earnings [at] wallstcheatsheet.com)